Currently, there are 82.53M common shares owned by the public and among those 76.02M shares have been available to trade.
The company’s stock has a 5-day price change of 21.43% and -63.58% over the past three months. STRO shares are trading -60.61% year to date (YTD), with the 12-month market performance down to -80.77% lower. It has a 12-month low price of $0.52 and touched a high of $5.17 over the same period. STRO has an average intraday trading volume of 1.48 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.35%, -33.96%, and -73.20% respectively.
Institutional ownership of Sutro Biopharma Inc (NASDAQ: STRO) shares accounts for 72.76% of the company’s 82.53M shares outstanding.
It has a market capitalization of $61.14M and a beta (3y monthly) value of 1.85. The earnings-per-share (ttm) stands at -$3.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.54% over the week and 13.98% over the month.
Earnings per share for the fiscal year are expected to increase by 30.93%, and 50.11% over the next financial year. EPS should grow at an annualized rate of 32.32% over the next five years, compared to -4.05% over the past 5-year period.
Wedbush coverage for the Sutro Biopharma Inc (STRO) stock in a research note released on March 14, 2025 offered a Neutral rating with a price target of $2. Citizens JMP was of a view on March 14, 2025 that the stock is Mkt Perform, while BofA Securities gave the stock Underperform rating on March 14, 2025, issuing a price target of $11- $1. BofA Securities on their part issued Buy rating on May 08, 2024.
